These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

547 related items for PubMed ID: 29115375

  • 1. Persistent STAT5-mediated ROS production and involvement of aberrant p53 apoptotic signaling in the resistance of chronic myeloid leukemia to imatinib.
    Cheng Y, Hao Y, Zhang A, Hu C, Jiang X, Wu Q, Xu X.
    Int J Mol Med; 2018 Jan; 41(1):455-463. PubMed ID: 29115375
    [Abstract] [Full Text] [Related]

  • 2. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
    Al-Jamal HA, Jusoh SA, Yong AC, Asan JM, Hassan R, Johan MF.
    Asian Pac J Cancer Prev; 2014 Jan; 15(11):4555-61. PubMed ID: 24969884
    [Abstract] [Full Text] [Related]

  • 3. Stellettin B induces apoptosis in human chronic myeloid leukemia cells via targeting PI3K and Stat5.
    Chen Y, Zhou Q, Zhang L, Zhong Y, Fan G, Zhang Z, Wang R, Jin M, Qiu Y, Kong D.
    Oncotarget; 2017 Apr 25; 8(17):28906-28921. PubMed ID: 28423649
    [Abstract] [Full Text] [Related]

  • 4. Emodin Inhibits Resistance to Imatinib by Downregulation of Bcr-Abl and STAT5 and Allosteric Inhibition in Chronic Myeloid Leukemia Cells.
    Wang XY, Sun GB, Wang YJ, Yan F.
    Biol Pharm Bull; 2020 Apr 25; 43(10):1526-1533. PubMed ID: 32999163
    [Abstract] [Full Text] [Related]

  • 5. The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistant BCR-ABL-expressing leukemia cells.
    Grimaudo S, Meli M, Di Cristina A, Ferro A, Pipitone MR, Romagnoli R, Simoni D, Dieli F, Tolomeo M.
    Anticancer Drugs; 2013 Apr 25; 24(4):384-93. PubMed ID: 23370613
    [Abstract] [Full Text] [Related]

  • 6. JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia.
    Aranda-Tavío H, Recio C, Martín-Acosta P, Guerra-Rodríguez M, Brito-Casillas Y, Blanco R, Junco V, León J, Montero JC, Gandullo-Sánchez L, McNaughton-Smith G, Zapata JM, Pandiella A, Amesty A, Estévez-Braun A, Fernández-Pérez L, Guerra B.
    Biomed Pharmacother; 2021 Dec 25; 144():112330. PubMed ID: 34673425
    [Abstract] [Full Text] [Related]

  • 7. Dasatinib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells.
    Nam S, Williams A, Vultur A, List A, Bhalla K, Smith D, Lee FY, Jove R.
    Mol Cancer Ther; 2007 Apr 25; 6(4):1400-5. PubMed ID: 17431118
    [Abstract] [Full Text] [Related]

  • 8. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
    Tsubaki M.
    Yakugaku Zasshi; 2018 Apr 25; 138(12):1461-1466. PubMed ID: 30504658
    [Abstract] [Full Text] [Related]

  • 9. Homoharringtonine suppresses imatinib resistance via the Bcl-6/p53 pathway in chronic myeloid leukemia cell lines.
    Wang Q, Ding W, Ding Y, Ma J, Qian Z, Shao J, Li Y.
    Oncotarget; 2017 Jun 06; 8(23):37594-37604. PubMed ID: 28410239
    [Abstract] [Full Text] [Related]

  • 10. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
    Hekmatshoar Y, Ozkan T, Altinok Gunes B, Bozkurt S, Karadag A, Karabay AZ, Sunguroglu A.
    Cell Mol Biol (Noisy-le-grand); 2018 May 15; 64(6):23-30. PubMed ID: 29808796
    [Abstract] [Full Text] [Related]

  • 11. STAT5 triggers BCR-ABL1 mutation by mediating ROS production in chronic myeloid leukaemia.
    Warsch W, Grundschober E, Berger A, Gille L, Cerny-Reiterer S, Tigan AS, Hoelbl-Kovacic A, Valent P, Moriggl R, Sexl V.
    Oncotarget; 2012 Dec 15; 3(12):1669-87. PubMed ID: 23458731
    [Abstract] [Full Text] [Related]

  • 12. The Role of STAT5 in Tyrosine Kinase Inhibitor (IMATINIB) Resistance in CML Patients.
    Putri A, Rinaldi I, Louisa M, Koesnoe S.
    Acta Med Indones; 2019 Oct 15; 51(4):348-352. PubMed ID: 32041920
    [Abstract] [Full Text] [Related]

  • 13. MicroRNA-221 sensitizes chronic myeloid leukemia cells to imatinib by targeting STAT5.
    Jiang X, Cheng Y, Hu C, Zhang A, Ren Y, Xu X.
    Leuk Lymphoma; 2019 Jul 15; 60(7):1709-1720. PubMed ID: 30516071
    [Abstract] [Full Text] [Related]

  • 14. A novel tubulin polymerization inhibitor, MPT0B206, downregulates Bcr-Abl expression and induces apoptosis in imatinib-sensitive and imatinib-resistant CML cells.
    Chen CW, Lee YL, Liou JP, Liu YH, Liu CW, Chen TY, Huang HM.
    Apoptosis; 2016 Sep 15; 21(9):1008-18. PubMed ID: 27344662
    [Abstract] [Full Text] [Related]

  • 15. Dual inhibition of STAT3 and STAT5 may overcome imatinib resistance in chronic myeloid leukemia.
    Yin L, Xu J, Wu W, Niu M, Li Z, Zhu F, Xu K.
    Hematology; 2023 Dec 15; 28(1):2224625. PubMed ID: 37345979
    [Abstract] [Full Text] [Related]

  • 16. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
    You L, Liu H, Huang J, Xie W, Wei J, Ye X, Qian W.
    Oncotarget; 2017 Jan 31; 8(5):7777-7790. PubMed ID: 27999193
    [Abstract] [Full Text] [Related]

  • 17. Cryptotanshinone suppresses key onco-proliferative and drug-resistant pathways of chronic myeloid leukemia by targeting STAT5 and STAT3 phosphorylation.
    Dong B, Liang Z, Chen Z, Li B, Zheng L, Yang J, Zhou H, Qu L.
    Sci China Life Sci; 2018 Sep 31; 61(9):999-1009. PubMed ID: 30054832
    [Abstract] [Full Text] [Related]

  • 18. Thymoquinone Induces Downregulation of BCR-ABL/JAK/STAT Pathway and Apoptosis in K562 Leukemia Cells.
    Al-Rawashde FA, Wan Taib WR, Ismail I, Johan MF, Al-Wajeeh AS, Al-Jamal HAN.
    Asian Pac J Cancer Prev; 2021 Dec 01; 22(12):3959-3965. PubMed ID: 34967577
    [Abstract] [Full Text] [Related]

  • 19. Pml and TAp73 interacting at nuclear body mediate imatinib-induced p53-independent apoptosis of chronic myeloid leukemia cells.
    Liu JH, Liu CC, Yen CC, Gau JP, Wang WS, Tzeng CH.
    Int J Cancer; 2009 Jul 01; 125(1):71-7. PubMed ID: 19291793
    [Abstract] [Full Text] [Related]

  • 20. miR-101 sensitizes K562 cell line to imatinib through Jak2 downregulation and inhibition of NF-κB target genes.
    Farhadi E, Zaker F, Safa M, Rezvani MR.
    Tumour Biol; 2016 Oct 01; 37(10):14117-14128. PubMed ID: 27517565
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.